Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
74.90
-1.30 (-1.71%)
At close: Mar 5, 2026, 4:00 PM EST
74.90
0.00 (0.00%)
After-hours: Mar 5, 2026, 4:10 PM EST
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Tarsus Pharmaceuticals stock have an average target of 80.56, with a low estimate of 51 and a high estimate of 105. The average target predicts an increase of 7.56% from the current stock price of 74.90.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 3 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $95 → $105 | Buy | Maintains | $95 → $105 | +40.19% | Feb 25, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $87 → $90 | Strong Buy | Maintains | $87 → $90 | +20.16% | Feb 25, 2026 |
| Barclays | Barclays | Buy Initiates $100 | Buy | Initiates | $100 | +33.51% | Dec 9, 2025 |
| Mizuho | Mizuho | Buy Initiates $100 | Buy | Initiates | $100 | +33.51% | Nov 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $84 → $87 | Strong Buy | Maintains | $84 → $87 | +16.15% | Nov 5, 2025 |
Financial Forecast
Revenue This Year
705.28M
from 451.36M
Increased by 56.26%
Revenue Next Year
892.00M
from 705.28M
Increased by 26.47%
EPS This Year
0.71
from -1.59
EPS Next Year
3.34
from 0.71
Increased by 373.33%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 750.6M | 951.0M | |||
| Avg | 705.3M | 892.0M | |||
| Low | 668.1M | 823.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 66.3% | 34.8% | |||
| Avg | 56.3% | 26.5% | |||
| Low | 48.0% | 16.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.37 | 4.95 | |||
| Avg | 0.71 | 3.34 | |||
| Low | -0.75 | 2.28 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 599.9% | |||
| Avg | - | 373.3% | |||
| Low | - | 223.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.